12 results · 28ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

HANAROSTENT Esophagus Upper (CCC)

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

RZ Medizintechnik GmbH

FDA UDI
RZ-Medizintechnik GmbH·04049197181945·Dittel-Bougies, slightly curved, 35.5 c...

RZ Medizintechnik GmbH

FDA UDI
RZ-Medizintechnik GmbH·04049197181938·Dittel Dilating Bougies Charr....

VERTACONNECT TLIF Cage

FDA 510(k)
FDA Class 2 ·Orthopedic

OXICOM CONTROL

FDA 510(k)
FDA Class 1 ·Clinical Chemistry

COBAS 6000 C (501) MODULE

FDA Adverse Event
Malfunction ·ROCHE DIAGNOSTICS·Product code JJE·April 3, 2018

NATURALYTE

FDA Adverse Event
Death ·FRESENIUS MEDICAL CARE NORTH AMERICA·Product code KPO·November 7, 2014

FINELINE II

FDA Adverse Event
Death ·CPI - DEL CARIBE·Product code NVN·September 19, 2011

RESERVOIR 3ML

FDA Adverse Event
Malfunction ·MEDTRONIC PUERTO RICO OPERATIONS CO.·Product code FRN·July 29, 2013

1823260-2017-02642

FDA Adverse Event
Malfunction ·November 17, 2017

MultiDiagnost Eleva; x-ray system. Product Codes: 708032, 708036

FDA Enforcement
Class II ·Terminated·Philips Electronics North America Corporation·August 10, 2016

Boston Scientific TELIGEN, Implantable Cardiac Defibrillator models E102, E110, the following models are not available in the US: models E103, E111, F102, F103, F110, F111. Sterilized using ethylene oxide. Product Usage: This family of implantable cardioverter defibrillators (ICDs) provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy. Boston Scientific implantable cardioverter defibrillators (ICDs) are indicated to provide ventricular antitachycardia pacing (ATP) and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014